EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study

Yuki Kobari, Nao Nakajima, Akira Saito, Nanaka Katsurayama, Toru Inakawa, Satoshi Kubota, Yuki Nemoto, Kazutaka Nakamura, Kouichi Nishimura, Hiroki Ishihara, Takafumi Yagisawa, Hironori Fukuda und 7 weitere

Anticancer Research · 2026-08 · 46 (8) · 4453-4460

DOI: 10.21873/anticanres.18301 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Anticancer Research, online erschienen am 29.07.2026. Verfasst von Yuki Kobari und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan; yuukikobari17@gmail.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellUrinary Bladder NeoplasmsAged, 80 and overFemaleHumansMaleAntibodies, MonoclonalProgression-Free SurvivalRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Enfortumab vedotinoctogenarianspembrolizumaburothelial carcinoma

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, Humanizedenfortumab vedotinpembrolizumab

Autor:innen und Institutionen

  • Department of Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan; yuukikobari17@gmail.com.
  • Department of Urology, Tokyo Women's Medical University, Adachi Medical Center, Tokyo, Japan.
  • Department of Urology, Saiseikai Kawaguchi General Hospital, Kawaguchi, Japan.
  • Department of Urology, Saiseikai Kazo Hospital, Kazo, Japan.
  • Department of Urology, Todachuo General Hospital, Toda, Japan.
  • Department of Urology, Joban Hospital, Iwaki, Japan.

Zitieren

APA

Kobari, Y., Nakajima, N., Saito, A., Katsurayama, N., Inakawa, T., Kubota, S., Nemoto, Y., Nakamura, K., Nishimura, K., Ishihara, H., Yagisawa, T., Fukuda, H., Yoshida, K., Iizuka, J., Shimmura, H., Hashimoto, Y., Kondo, T., Kobayashi, H., & Takagi, T. (2026). Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Anticancer Research, 46(8), 4453-4460. https://doi.org/10.21873/anticanres.18301

Vancouver

Kobari Y, Nakajima N, Saito A, Katsurayama N, Inakawa T, Kubota S, et al. Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Anticancer Research. 2026;46(8):4453-4460. doi:10.21873/anticanres.18301

BibTeX
@article{Kobari2026,
  author = {Kobari, Yuki and Nakajima, Nao and Saito, Akira and Katsurayama, Nanaka and Inakawa, Toru and Kubota, Satoshi and Nemoto, Yuki and Nakamura, Kazutaka and Nishimura, Kouichi and Ishihara, Hiroki and Yagisawa, Takafumi and Fukuda, Hironori and Yoshida, Kazuhiko and Iizuka, Junpei and Shimmura, Hiroaki and Hashimoto, Yasunobu and Kondo, Tsunenori and Kobayashi, Hiroshi and Takagi, Toshio},
  title = {Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study},
  journal = {Anticancer Research},
  year = {2026},
  volume = {46},
  number = {8},
  pages = {4453--4460},
  doi = {10.21873/anticanres.18301}
}
Kostenlos starten →